Skip to content
MarketScale
‹ Back to IndustriesHealthcare

PRESCO OFFERS CUSTOMERS A CHOICE IN MEDICAL GRADE FILMS

In the past, PVC was the material used in medical grade film due to the many custom formulations and emboss patterns available. Today, however, the healthcare industry increasingly demands a choice of non-PVC films as well. Presco has responded. Let’s take a look at Presco’s wide-ranging capabilities in medical grade films. At Presco, our mission…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

In the past, PVC was the material used in medical grade film due to the many custom formulations and emboss patterns available. Today, however, the healthcare industry increasingly demands a choice of non-PVC films as well. Presco has responded. Let’s take a look at Presco’s wide-ranging capabilities in medical grade films.

At Presco, our mission is to supply the medical and healthcare market with as many film options as possible. For example, PVC film can be laminated to a non-woven fabric to create a soft skin contact film for use in blood pressure cuffs and DVT sleeves. We also offer PVC/TPU (Thermoplastic Polyurethane) film blends. TPU plastics have many desirable properties including elasticity, transparency, as well as resistance to oil, grease, and abrasion, making them suitable for inflatable products like mattresses or cushions.

Presco also offers many plasticizer options for PVC film to soften and increase the flexibility of the brittle PVC polymer. Plasticizers include DEHP (Di(2-ethylhexyl)phthalate) as well as non-phthalates. Products that may contain plasticized PVC include bags for IV drips, blood, peritoneal dialysis, and enteral nutrition feeding, as well as tubing for umbilical artery catheters, infusions, and cardiopulmonary bypass procedures.

Regulatory concerns in some medical segments led to the desire for medical film that doesn’t contain PVC. That’s why Presco developed manufacturing capabilities to extrude Pres-Flex EVA (Ethylene Vinyl Acetate). EVA is a member of the polyolefin family, meaning it’s plasticizer-free, unlike PVC. Non-PVC films are highly specialized and are not widely available. EVA film extrusion is a new capability for Presco and marks the first PVC-free manufacturing capability for Pres-Flex Engineered Film. Pres-Flex EVA film is available in multiple emboss patterns such as matte, taffeta, or a smooth suede.

Presco has polymer chemists on staff, as well as a full R&D lab, making it possible to customize formulations and compound films to meet your specific film needs. We offer in-house blending and compounding systems, various in-line emboss rolls, and off-line slitting capabilities down to 1″ width to satisfy your unique specifications. We also have the ability for in-line lamination, which uses heat and pressure as opposed to adhesives.

As the market matures and shifts, there is a need to offer a wide range of medical films. These materials also must meet regulatory compliance relating to non-DEHP films. You can feel confident partnering with Presco for our deep industry knowledge and extensive expertise in a variety of medical films, including PVC, TPU, EVA, and many other customized variations. Our capabilities give you options, so you can work with one supplier for all your medical film needs.

Read more at pres-flex.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512